drugset / Trial / NCT00350545
A Phase 2 Trial of Rituximab and Corticosteroid Therapy for Newly Diagnosed Chronic Graft Versus Host Disease
NaSingle-groupOpen-labelTreatment
Summary
The addition of rituximab to prednisone for the initial treatment of chronic GVHD will increase the overall response rate, enable a more rapid and effective steroid taper.
Timeline
- Start
- 2006-08
- Primary completion
- 2012-05
- Completion
- 2014-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Rituximab | Monoclonal antibody | 375 mg/m2 | Intravenous |
| Background | Cyclosporine | Peptide | — | — |
| Background | Prednisone | Other / unclassified | 1 mg/kg | Oral |
| Background | Tacrolimus | Small molecule | — | — |